FOLR1 and peritoneum cancer: It was granted accelerated approval by the FDA in November 2022, for adult patients with folate receptor alpha (FRα) positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatment regimens.